ES2105611T3 - Adnc de la ciclooxigenasa-2 humana y ensayo para evaluar la inhibicion de la cilooxigenasa-2. - Google Patents

Adnc de la ciclooxigenasa-2 humana y ensayo para evaluar la inhibicion de la cilooxigenasa-2.

Info

Publication number
ES2105611T3
ES2105611T3 ES94902571T ES94902571T ES2105611T3 ES 2105611 T3 ES2105611 T3 ES 2105611T3 ES 94902571 T ES94902571 T ES 94902571T ES 94902571 T ES94902571 T ES 94902571T ES 2105611 T3 ES2105611 T3 ES 2105611T3
Authority
ES
Spain
Prior art keywords
human
assay
inhibition
cyclooxigenasa
cilooxigenasa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94902571T
Other languages
English (en)
Inventor
Wanda A Cromlish
Brian P Kennedy
Gary O'neill
Philip J Vickers
Elizabeth Wong
Joseph A Mancini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Frosst Canada and Co
Original Assignee
Merck Frosst Canada and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26744337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2105611(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Frosst Canada and Co filed Critical Merck Frosst Canada and Co
Application granted granted Critical
Publication of ES2105611T3 publication Critical patent/ES2105611T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083—Miscellaneous (1.14.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/61—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving triglycerides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/99—Miscellaneous (1.14.99)
    • C12Y114/99001—Prostaglandin-endoperoxide synthase (1.14.99.1), i.e. cyclooxygenase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90241—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

LA INVENCION SE REFIERE A UN ENSAYO PARA MEDIR LA INHIBICION DE LA CICLOOXIGENASA-2 EN COMPARACION CON LA CICLOOXIGENASA-1. LA INVENCION TAMBIEN COMPRENDE CDNA DE CICLOOXIGENASA-2 HUMANA Y UNA CICLOOXIGENASA-2 HUMANA.
ES94902571T 1992-12-22 1993-12-17 Adnc de la ciclooxigenasa-2 humana y ensayo para evaluar la inhibicion de la cilooxigenasa-2. Expired - Lifetime ES2105611T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99476092A 1992-12-22 1992-12-22
US08/064,271 US5543297A (en) 1992-12-22 1993-05-06 Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity

Publications (1)

Publication Number Publication Date
ES2105611T3 true ES2105611T3 (es) 1997-10-16

Family

ID=26744337

Family Applications (2)

Application Number Title Priority Date Filing Date
ES96201845T Expired - Lifetime ES2168436T3 (es) 1992-12-22 1993-12-17 Ensayo para determinar la actividad de ciclooxigenasa 1.
ES94902571T Expired - Lifetime ES2105611T3 (es) 1992-12-22 1993-12-17 Adnc de la ciclooxigenasa-2 humana y ensayo para evaluar la inhibicion de la cilooxigenasa-2.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES96201845T Expired - Lifetime ES2168436T3 (es) 1992-12-22 1993-12-17 Ensayo para determinar la actividad de ciclooxigenasa 1.

Country Status (11)

Country Link
US (2) US5543297A (es)
EP (3) EP0736769B1 (es)
JP (2) JP3608622B2 (es)
AT (2) ATE210826T1 (es)
AU (1) AU5690694A (es)
CA (1) CA2151231C (es)
DE (2) DE69312513T2 (es)
DK (1) DK0675964T3 (es)
ES (2) ES2168436T3 (es)
GR (1) GR3025111T3 (es)
WO (1) WO1994014977A1 (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837479A (en) * 1992-09-22 1998-11-17 Young; Donald A. Screening assays for inhibitors of mammalian prostaglandin H synthase-2
WO1995009238A1 (en) * 1993-09-27 1995-04-06 Merck Frosst Canada Inc. High level expression of human cyclooxygenase-2
CA2179168A1 (en) * 1993-12-17 1995-06-22 Douglas A. Kniss Antisense oligonucleotides to suppress eicosanoid formation
US5622948A (en) * 1994-12-01 1997-04-22 Syntex (U.S.A.) Inc. Pyrrole pyridazine and pyridazinone anti-inflammatory agents
AT401061B (de) * 1995-01-26 1996-06-25 Hafslund Nycomed Pharma Benutzung einer menschlichen monozytenartigen zellinie zur identifikation und bestimmung von substanzen zur hemmung des menschlichen enzyms cyclooxygenase-2
WO1996040720A1 (en) * 1995-06-07 1996-12-19 University Of Rochester Mammalian prostaglandin h synthase-2
JPH0977664A (ja) * 1995-09-13 1997-03-25 Yakult Honsha Co Ltd シクロオキシゲナーゼ−２特異的阻害剤及び抗炎症剤
EP0889724A1 (en) * 1996-02-27 1999-01-13 Rpms Technology Limited Cox-2 selective inhibitors for managing labour and uterine contractions
AT402936B (de) * 1996-05-29 1997-09-25 Nycomed Austria Gmbh Benutzung einer menschlichen zellinie zur identifikation und bestimmung von substanzen zur hemmung der induktion der expression des cyclooxygenase-2-genes
GB2319032A (en) * 1996-10-04 1998-05-13 Merck & Co Inc Crystals of human cyclooxygenase-2 (hCOX-2)
US5985930A (en) 1996-11-21 1999-11-16 Pasinetti; Giulio M. Treatment of neurodegenerative conditions with nimesulide
EP1138324A1 (en) * 1996-11-21 2001-10-04 The Mount Sinai School of Medicine of New York University Treatment of neurodegenerative conditions with nimesulide
US6200760B1 (en) * 1997-02-24 2001-03-13 Cornell Research Foundation, Inc. Method of screening agents as candidates for drugs or sources of drugs
EP1006794B1 (en) * 1997-03-12 2007-11-28 Robert W. Esmond A method for treating or preventing alzheimer's disease
PT1037927E (pt) 1997-12-08 2004-10-29 Emd Lexigen Res Ct Corp Proteinas de fusao heterodimericas uteis para imunoterapia de abordagem selectiva e estimulacao imunologica geral
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
ATE329622T1 (de) * 1998-04-15 2006-07-15 Lexigen Pharm Corp Steigerung der antikörper-zytokin- fusionsproteinmediierten immunantwort durch mitverabreichung mit einem angiogeneseinhibitor
US7122360B1 (en) 1998-06-24 2006-10-17 University Of Dundee Polypeptides, polynucleotides and uses thereof
CA2347365A1 (en) * 1998-10-23 2000-05-04 Merck Frosst Canada & Co. Combination product comprising an e-type prostaglandin ligand and a cox-2 selective inhibitor and methods of use
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
GB9827430D0 (en) * 1998-12-11 1999-02-03 Ludwig Inst Cancer Res Differential expression in primary breast cancer
US6649645B1 (en) 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
AU5615200A (en) * 1999-06-16 2001-01-02 Temple University - Of The Commonwealth System Of Higher Education Cell-based assay for screening cox-2 inhibitors
US6933128B1 (en) 1999-06-16 2005-08-23 Temple University-Of The Commonwealth System Of Higher Education Cell-based assay for screening cox-2 inhibitors
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2001011026A1 (en) * 1999-08-06 2001-02-15 G.D. Searle & Co. Canine cyclooxygenase-1 (cox-1) and cyclooxygenase-2 (cox-2)
BR0013231A (pt) 1999-08-09 2002-07-23 Lexigen Pharm Corp Complexos citocina-anticorpo múltiplos
EP1228214A2 (en) 1999-11-12 2002-08-07 MERCK PATENT GmbH Erythropoietin forms with improved properties
EA008242B1 (ru) * 1999-12-08 2007-04-27 Фармация Корпорейшн Композиции на основе ингибитора циклооксигеназы-2 с быстро наступающим терапевтическим действием и способы лечения заболеваний
ES2328446T5 (es) * 2000-02-04 2014-02-27 Children's Hospital Research Foundation Uso de lipasa ácida lisosomal para tratar la aterosclerosis y enfermedades asociadas
JP5179689B2 (ja) * 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
JP5390055B2 (ja) * 2000-06-29 2014-01-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 免疫サイトカインの取り込み増強剤との併用治療による抗体−サイトカイン融合タンパク質媒介免疫応答の増強
AU5754701A (en) * 2000-07-13 2002-01-30 Pharmacia Corp Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2mediated disorders
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
NZ524252A (en) * 2000-07-20 2004-03-26 Lauras As Cox-2 inhibitors for treating HIV and AIDS
AU8475301A (en) * 2000-08-07 2002-02-18 Univ Vanderbilt Detection of cox-2 activity and anandamide metabolites
US6783943B2 (en) * 2000-12-20 2004-08-31 The Regents Of The University Of California Rolling circle amplification detection of RNA and DNA
US20020164617A1 (en) * 2000-12-29 2002-11-07 Neogenesis Pharmaceuticals, Inc. Affinity selection-based screening of hydrophobic proteins
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
HUP0303428A2 (hu) * 2001-03-07 2004-01-28 Merck Patent Gmbh. Expressziós eljárás hibrid izotípusú antitestcsoportot tartalmazó fehérjékhez
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
PE20021017A1 (es) 2001-04-03 2002-11-24 Pharmacia Corp Composicion parenteral reconstituible
KR100900166B1 (ko) 2001-05-03 2009-06-02 메르크 파텐트 게엠베하 재조합 종양 특이적 항체 및 이들의 용도
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
AU2002340063B2 (en) * 2001-09-28 2007-05-10 Brigham Young University Novel cyclooxygenase variants and methods of use
ATE542137T1 (de) * 2001-12-04 2012-02-15 Merck Patent Gmbh Immunocytokine mit modulierter selektivität
PT3072978T (pt) 2002-05-09 2018-10-15 Brigham & Womens Hospital Inc 1l1rl-1 como um marcador de doença cardiovascular
US7314709B2 (en) * 2002-08-06 2008-01-01 Vanderbilt University Compositions and methods for detecting and quantifying COX-2 activity by lipoamino acid metabolism
CN100432105C (zh) * 2002-12-17 2008-11-12 默克专利有限公司 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
DK2384753T3 (en) 2003-08-29 2016-04-11 Brigham & Womens Hospital Hydantoin derivatives as inhibitors of cell necrosis
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
CA2624601C (en) 2004-10-06 2018-07-03 The Brigham And Women's Hospital, Inc. Relevance of achieved levels of markers of systemic inflammation following treatment
JP2008528626A (ja) * 2005-01-31 2008-07-31 マイラン ラボラトリーズ インク． ヒドロキシル化されたネビボロールを含む薬学的組成物
US7358237B2 (en) * 2005-04-28 2008-04-15 The Johns Hopkins University Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2
KR101310037B1 (ko) 2005-05-31 2013-09-24 밀란 인크. 네비볼롤을 함유하는 조성물
WO2007030375A2 (en) * 2005-09-08 2007-03-15 Children's Hospital Medical Center Lysosomal acid lipase therapy for nafld and related diseases
US8119358B2 (en) * 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
EP3279663B1 (en) 2006-03-15 2021-07-28 The Brigham and Women's Hospital, Inc. Use of gelsolin to diagnose and treat inflammatory diseases
US8299043B2 (en) 2006-04-28 2012-10-30 Mayo Foundation For Medical Education And Research Treating glaucoma, cardiovascular diseases, and renal diseases
CA2659082A1 (en) * 2006-06-07 2007-12-21 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
BRPI0810409A2 (pt) 2007-04-18 2015-02-18 Thethys Bioscience Inc Biomarcadores relacionados ao diabetes e métodos de uso destes
TW201201764A (en) 2010-02-01 2012-01-16 Hospital For Sick Children Remote ischemic conditioning for treatment and prevention of restenosis
SG10201908570RA (en) 2010-03-31 2019-11-28 Hospital For Sick Children Use of remote ischemic conditioning to improve outcome after myocardial infarction
EP2968276A4 (en) 2013-03-15 2017-02-15 President and Fellows of Harvard College Hybrid necroptosis inhibitors
RU2706366C2 (ru) * 2017-11-01 2019-11-18 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермская государственная фармацевтическая академия" Министерства здравоохранения Российской Федерации (ФГБОУ ВО ПГФА Минздрава России) Способ отбора противовоспалительных средств с использованием рассчитанных энергий взаимодействия с ферментами циклооксигеназ 1 и 2
AU2019345067A1 (en) 2018-09-19 2021-04-08 Modernatx, Inc. High-purity peg lipids and uses thereof
US12151029B2 (en) 2018-09-19 2024-11-26 Modernatx, Inc. PEG lipids and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4562155A (en) * 1983-05-19 1985-12-31 The Wistar Institute Of Anatomy And Biology Hybrid viral plasmid and microorganisms containing same
JPS63157980A (ja) 1986-12-22 1988-06-30 Chisso Corp プロスタグランジン合成酵素の安定化方法
JPH01228479A (ja) * 1988-03-10 1989-09-12 Meiji Milk Prod Co Ltd プロスタグランジンエンドペルオキシドシンテターゼをコードするｄｎａ
US6048850A (en) 1992-09-22 2000-04-11 Young; Donald A. Method of inhibiting prostaglandin synthesis in a human host
US5837479A (en) 1992-09-22 1998-11-17 Young; Donald A. Screening assays for inhibitors of mammalian prostaglandin H synthase-2
NZ256776A (en) * 1992-09-22 1997-10-24 Univ Rochester Transgenic mammalian cells containing a dna sequence expressing pghs-2
JPH06315798A (ja) * 1993-05-07 1994-11-15 Kobe Steel Ltd 高エネルギービーム溶接用裏当材

Also Published As

Publication number Publication date
JPH08504584A (ja) 1996-05-21
EP0675964B1 (en) 1997-07-23
EP1130110A2 (en) 2001-09-05
USRE39696E1 (en) 2007-06-19
JP3608622B2 (ja) 2005-01-12
GR3025111T3 (en) 1998-01-30
EP1130110A3 (en) 2005-02-23
JP3573743B2 (ja) 2004-10-06
AU5690694A (en) 1994-07-19
EP0675964A1 (en) 1995-10-11
HK1027471A1 (en) 2001-01-12
DE69331340T2 (de) 2002-08-22
ATE155811T1 (de) 1997-08-15
DK0675964T3 (da) 1997-09-15
CA2151231A1 (en) 1994-07-07
CA2151231C (en) 2004-11-09
DE69331340D1 (de) 2002-01-24
EP0736769B1 (en) 2001-12-12
ES2168436T3 (es) 2002-06-16
US5543297A (en) 1996-08-06
JP2004081211A (ja) 2004-03-18
WO1994014977A1 (en) 1994-07-07
DE69312513D1 (de) 1997-08-28
DE69312513T2 (de) 1998-01-15
EP0736769A1 (en) 1996-10-09
ATE210826T1 (de) 2001-12-15

Similar Documents

Publication Publication Date Title
CA2151231A1 (en) Human cyclooxygenase-2cdna and assays for evaluating cyclooxygenase-2 activity
NL184999B (nl) Pleister met werking tegen pijn en ontstekingen.
MX9203107A (es) 6-n-propil-8-metoximetil o metilmercaptometil-ergolinas y composiciones farmaceuticas que las contienen.
ES2192708T3 (es) Combinaciones de productos activos fungicidas.
TR199902545T2 (xx) Kalp damar hastal�klar�n�n �nlenmesinde siklooksijenaz-2 inhibit�rlerini kullanma y�ntemi
IT1137218B (it) Agenti che provocano un ritardo nella propagazione della fiamma
ES2043648T3 (es) Estuche de cosmetico y aplicador.
IT8919676A0 (it) Dispersioni acquose di fotoiniziatori e loro impiego.
IT7925600A0 (it) Perfezionamenti nella costruzionedi una valvola elettromagnetica.
BR8205294A (pt) Produtos de adicao de condensados trietanolaminicos e eteres bisglicidilicos e sua aplicacao
IT8122273A0 (it) Complesso di fissaggio costituito da un tassello ad espansione e da una vite di fissaggio.
BR8000263A (pt) Dispersoes de pigmento e sua aplicacao
IT8121425A0 (it) Procedimento per la fosfatazione di superfici metalliche e sua applicazione.
NL187367B (nl) Samenstel van buizen en koppelstukken.
BR9205297A (pt) Novos peptideos antipatogenicos e composicoes que os contem
BR9205969A (pt) Novas toxinas ativas contra nematóides e genes que codificam as mesmas
IT1170489B (it) Video-gioco ad interrogazione e risposta
IT7829877A0 (it) Accoppiatore rapido di linea ditrasmissione o periferiche di ordinatore utilizzante una particolare struttura di microistruzioni.
IT1121646B (it) Impastatrice e mescolatrice azionata elettronicamente
IT7925866A0 (it) Angolare di raccordo di guida d'onde rettangolare piegato sulla faccia maggiore della guida d'onde.
IT1194975B (it) Giunto a snodo omocinetico e relativo procedimento di costruzione
TR21311A (tr) Bazi 1-(3,5-diklorobenzoil) -3-fenilplirazolin'ler ve bunlarin mild@'y* yok etmek icin kullanilmasi
BR8205491A (pt) Laminado protetor contra corrosao e sua producao
IT7922686A0 (it) Inibizione della dealogenazione nella riduzione di cloronitrobenzoli.
IT8017931A0 (it) Perfezionamenti e innovazioni sull'effetto acustico derivante dalla utilizzazione di una linea di ritardo

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 675964

Country of ref document: ES